[144] Guardant Health, Inc. SEC Filing

Rhea-AI Filing Summary

Guardant Health, Inc. (GH) Form 144 reports a proposed sale of 26 common shares by a person associated with the issuer, to be executed approximately on 09/17/2025 through Charles Schwab & Co., Inc. The shares arose from a restricted stock lapse on 09/15/2025 and were issued as equity compensation. The filing lists 26 shares outstanding to be sold with an aggregate market value shown as $1,446.00 and total company shares outstanding at 124,705,857. The form also discloses three prior small sales by the same seller of 26 shares each on 06/18/2025, 07/17/2025, and 08/19/2025 with gross proceeds of $1,286, $1,253, and $1,535 respectively.

Positive

• Shares originated from restricted stock lapse, confirming vesting and lawful acquisition
• Sale to be executed through a registered broker (Charles Schwab), consistent with standard market procedures
• Small size relative to total outstanding shares (26 vs 124,705,857), indicating immateriality to capitalization

Negative

• Multiple recent small sales in the past three months (26 shares on three dates) which may be perceived as ongoing insider selling
• No 10b5-1 plan date provided in the remarks section to clarify pre-planned sales execution

Insights

Securities/Equity Analyst

TL;DR: Routine insider vesting and small-scale sale; immaterial to capitalization.

The filing documents a post-vesting sale of 26 shares by an individual following a restricted stock lapse, executed through Charles Schwab on NASDAQ. Given the company’s outstanding share count of 124,705,857, the quantity and aggregate market value ($1,446) are immaterial to GH’s capitalization and are unlikely to affect market dynamics. Prior three-month sales totaling 78 shares suggest periodic monetization of vested small equity awards rather than a large, concentrated disposition.

Compliance / Corporate Governance Expert

TL;DR: Filing appears to be a standard Rule 144 notice tied to equity compensation vesting.

The notice includes the required representations regarding absence of undisclosed material information and indicates the shares resulted from equity compensation via restricted stock lapse. The use of a registered broker and the attestation language align with Rule 144 procedures. No dates for plan adoption or 10b5-1 plan are provided, and the filing contains no statements of material adverse information; the disclosure meets the basic procedural requirements for reporting a planned sale.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Charles Schwab & Co., Inc. 3000 Schwab Way Westlake TX 76262	26	1446.00	124705857	09/17/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/15/2025	Restricted Stock Lapse	Guardant Health, Inc.			26	09/15/2025	Equity Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
MYRTLE S POTTER 3100 HANOVER STREET PALO ALTO CA 94303	Guardant Health, Inc.	06/18/2025	26	1286.00
MYRTLE S POTTER 3100 HANOVER STREET PALO ALTO CA 94303	Guardant Health, Inc.	07/17/2025	26	1253.00
MYRTLE S POTTER 3100 HANOVER STREET PALO ALTO CA 94303	Guardant Health, Inc.	08/19/2025	26	1535.00

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Guardant Health (GH) Form 144 filed here report?

It reports a proposed sale of 26 common shares arising from a restricted stock lapse, to be sold around 09/17/2025 via Charles Schwab on NASDAQ.

How large is the proposed sale relative to GH's outstanding shares?

The filing lists GH's outstanding shares as 124,705,857; the proposed sale of 26 shares is immaterial to total capitalization.

Were there recent sales by the same seller?

Yes. The seller recorded three sales of 26 shares each on 06/18/2025, 07/17/2025, and 08/19/2025 with gross proceeds of $1,286, $1,253, and $1,535 respectively.

What was the acquisition method for the shares being sold?

The shares were acquired via a restricted stock lapse on 09/15/2025 and the consideration type is listed as equity compensation.

Which broker and exchange are involved in the proposed sale?

The broker listed is Charles Schwab & Co., Inc. and the sale is planned on NASDAQ.